Research News and Research

RSS

Advances in health IT

The New York Times: A "broad transformation in health care underway" is "fueled in good part by technology" that "promises to shift a lot of the diagnosis, monitoring and treatment of disease from hospitals and specialized clinics, where treatment is expensive, to primary care physicians and patients themselves — at far less cost."

25 May 2010

Obama's health IT leader says doctors will embrace change

Irene Wielawski writes for Kaiser Health News that electronic medical records may be as important as stethoscopes. "Dr. David Blumenthal was not happy to find a new computer installed on his desk when he showed up for work one morning eight years ago at Massachusetts General Hospital in Boston.

25 May 2010

Delphinus Medical Technologies secures $8M in venture capital to commercialize SoftVue system

The Barbara Ann Karmanos Cancer Institute announced today that its spin-off company Delphinus Medical Technologies, LLC, has secured $8 million in venture capital to start the commercialization process of SoftVue, an alternative to mammography.

25 May 2010

STOP Obesity Alliance researchers receive $250,000 donation to research on health impact of obesity

The research team of The George Washington University School of Public Health and Health Services' Department of Health Policy's Strategies to Overcome and Prevent Obesity Alliance received a $250,000 donation from Allergan, Inc. to support public health, policy analysis and research about the economic and health impact of obesity and related chronic diseases.

25 May 2010

DU receives $17.5M as gift to establish Knoebel Center for the Study of Aging

Betty Knoebel, widow of Denver food services pioneer Ferdinand "Fritz" Knoebel, has given the University of Denver $17.5 million, among the largest gifts in its history. DU will use the gift to establish the Knoebel Center for the Study of Aging and to support the School of Hotel, Restaurant and Tourism Management in DU's Daniels College of Business.

25 May 2010

Florida health care providers offer language services, medical homes

As "the region continues to attract residents from all over the country and the world, local health care providers and educators are searching for ways to better serve them." Some use "cultural toolkits," and have guides to help providers relate to patients' cultural and religious preferences. "'From a business perspective, it makes a lot of sense,' said Bernardo Ramirez, assistant professor of health services administration at the University of Central Florida.

24 May 2010

Scientists develop DNA-vaccine that restricts supply of blood to tumours

A DNA-vaccine that restricts the supply of blood to tumours has been developed by scientists at the Swedish medical university Karolinska Institutet. The vaccine slows the growth of breast cancer tumours in mice.

24 May 2010

Research work holds promise for biological substitute for dental implants

A technique pioneered in the Tissue Engineering and Regenerative Medicine Laboratory of Dr. Jeremy Mao, the Edward V. Zegarelli Professor of Dental Medicine at Columbia University Medical Center, can orchestrate stem cells to migrate to a three-dimensional scaffold infused with growth factor, holding the translational potential to yield an anatomically correct tooth in as soon as nine weeks once implanted.

24 May 2010

Somanetics' Vital Sync bedside monitor system receives FDA clearance

Somanetics Corporation announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration to expand features on its Vital Sync bedside monitor and research data aggregation system. The clearance allows for interface with a broader range of bedside devices, display of derived parameters of calculated clinical indices, and an automated events trigger to alert clinicians when patient parameters fall outside desired thresholds.

24 May 2010

Repligen's RG2833 granted orphan drug designation for treatment of Friedreich's ataxia

Repligen Corporation announced today that the Office of Orphan Products Development of the Food and Drug Administration has granted orphan drug designation to RG2833, a selective histone deacetylase 3 inhibitor for the treatment of Friedreich's ataxia. Orphan drug designation qualifies Repligen to receive seven years of marketing exclusivity in the United States if the company is the first to obtain marketing approval for RG2833 for the treatment of Friedreich's ataxia.

24 May 2010

Hospitals facing new payment squeezes

News outlets report on payment issues for hospitals, including those stemming from the new health law.

24 May 2010

Today's OpEds: Taxing health plans, a health care 'loophole,' NY Times on medical loss ratio

Few Americans know what a "medical loss ratio" is, but a fierce struggle over how to calculate it under the new health care reform law will determine how much insurers must spend on patient care and how much they can retain for administration and profits. This is but one of many battles that will emerge as federal and state regulators develop regulations to implement reform (5/23).

24 May 2010

Dialog Medical becomes newest Affinity Program Partner of AUA

Dialog Medical, the leading provider of informed consent and patient education systems for physician practices and hospitals, today announced that it has become the newest Affinity Program Partner of the American Urological Association.

24 May 2010

Lawmakers could vote this week on three-year 'doc fix,' COBRA subsidy extension

Before they leave for the Memorial Day recess, lawmakers face legislation which includes a provision on Medicare payments to physicians and an extension of the COBRA subsidy to newly laid-off workers.

24 May 2010

Thymosin beta 4 reduces brain tissue damage, improves brain function in rats: Research paper

RegeneRx Biopharmaceuticals, Inc. announced today that in a preclinical research paper published in the May 2010 issue of the Journal of Neurosurgery, (online ahead of publication), scientists found that the systemic administration of thymosin beta 4, or Tβ4, significantly reduced brain tissue damage and improved brain function in rats with traumatic brain injury, or TBI.

24 May 2010

Study: Health law could mean penalties for one in three employers

News outlets covered analyses of health law provisions affecting businesses. "About one-third of employers subject to major requirements of the new health care law may face tax penalties because they offer health insurance that could be considered unaffordable to some employees, a new study says," The New York Times reports.

24 May 2010

Expression Analysis agrees to purchase PacBio RS DNA sequencing system from Pacific Biosciences

Expression Analysis, a leading provider of genomic services for clinical trials and research, announced today that it has agreed to purchase a PacBio RS DNA sequencing system from northern-California based Pacific Biosciences, whose third-generation DNA sequencing technology is expected to revolutionize the field of genetic analysis through the use of single molecule real time detection of biological events.

24 May 2010

Dole Nutrition Handbook recognized with prestigious Living Now Book Award

Dole Food Company, Inc. is pleased to have received the prestigious Living Now Book Award for the Dole Nutrition Handbook: What You Need to Eat And How To Live For A Longer Healthier Life. The gold medal award is the top honor in the competition's Nutrition & Diet category. On Earth Day each year, the Jenkins Group - an organization dedicated to promoting books that enrich readers' lives in Earth friendly ways - presents the Living Now Book Awards to honor "books for better living."

24 May 2010

ZyGEM announces acquisition of MicroLab Diagnostics

ZyGEM Corp. Ltd., today announced that it has acquired MicroLab Diagnostics Inc., a private company developing microfluidic devices for rapid DNA testing. ZyGEM intends to market products integrating its unique DNA extraction and reagents and detection assays with the breakthrough microfluidic chip technology developed by MicroLab, which will operate as a business unit of the new company.

24 May 2010

Salix Pharmaceuticals announces availability of Xifaxan tablets for reducing risk of overt HE recurrence

Salix Pharmaceuticals, Ltd. today announced the availability of Xifaxan (rifaximin) 550 mg tablets for the reduction in risk of overt hepatic encephalopathy recurrence in patients 18 years of age or older. Those HE patients may now fill their Xifaxan 550 mg prescriptions in U.S. pharmacies and should speak with their doctors about this important treatment option.

24 May 2010